WO2023034467A3 - Cgrp antagonists for treating skin conditions - Google Patents

Cgrp antagonists for treating skin conditions Download PDF

Info

Publication number
WO2023034467A3
WO2023034467A3 PCT/US2022/042283 US2022042283W WO2023034467A3 WO 2023034467 A3 WO2023034467 A3 WO 2023034467A3 US 2022042283 W US2022042283 W US 2022042283W WO 2023034467 A3 WO2023034467 A3 WO 2023034467A3
Authority
WO
WIPO (PCT)
Prior art keywords
skin conditions
treating skin
methods
cgrp antagonists
treating
Prior art date
Application number
PCT/US2022/042283
Other languages
French (fr)
Other versions
WO2023034467A2 (en
Inventor
Robert CROOP
Daniel FRANJIC
Original Assignee
Pfizer Ireland Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ireland Pharmaceuticals filed Critical Pfizer Ireland Pharmaceuticals
Publication of WO2023034467A2 publication Critical patent/WO2023034467A2/en
Publication of WO2023034467A3 publication Critical patent/WO2023034467A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Abstract

Provided for are methods of treating skin conditions with one or more CGRP receptor antagonists and/or pharmaceutical compositions thereof. Such methods are useful for treating, ameliorating, alleviating, providing for prophylaxis or prevention of, halting the progression of, and/or reducing the risk of one or more skin conditions in a mammalian subject, such as a human. In particular, CGRP receptor antagonists such as those according to Formula I, Formula II, and/or Formula III as described herein are useful in methods of treating skin conditions in a subject in need thereof.
PCT/US2022/042283 2021-09-02 2022-09-01 Cgrp antagonists for treating skin conditions WO2023034467A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163240071P 2021-09-02 2021-09-02
US63/240,071 2021-09-02

Publications (2)

Publication Number Publication Date
WO2023034467A2 WO2023034467A2 (en) 2023-03-09
WO2023034467A3 true WO2023034467A3 (en) 2023-04-13

Family

ID=85412859

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/042283 WO2023034467A2 (en) 2021-09-02 2022-09-01 Cgrp antagonists for treating skin conditions

Country Status (2)

Country Link
AR (1) AR126955A1 (en)
WO (1) WO2023034467A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090258866A1 (en) * 2008-04-11 2009-10-15 Bristol-Myers Squibb Company CGRP Receptor Antagonists
WO2017001434A1 (en) * 2015-06-29 2017-01-05 Galderma Research & Development Cgrp receptor antagonist compounds for topical treatment of skin disorders
WO2021005494A1 (en) * 2019-07-05 2021-01-14 Allergan Pharmaceuticals International Limited Cgrp antagonists and clostridial derivatives for the treatment of neuropsychiatric and neurological disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090258866A1 (en) * 2008-04-11 2009-10-15 Bristol-Myers Squibb Company CGRP Receptor Antagonists
WO2017001434A1 (en) * 2015-06-29 2017-01-05 Galderma Research & Development Cgrp receptor antagonist compounds for topical treatment of skin disorders
WO2021005494A1 (en) * 2019-07-05 2021-01-14 Allergan Pharmaceuticals International Limited Cgrp antagonists and clostridial derivatives for the treatment of neuropsychiatric and neurological disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DUBOWCHIK GENE M., CONWAY CHARLES M., XIN ALISON W.: "Blocking the CGRP Pathway for Acute and Preventive Treatment of Migraine: The Evolution of Success", JOURNAL OF MEDICINAL CHEMISTRY, vol. 63, no. 13, 9 July 2020 (2020-07-09), US , pages 6600 - 6623, XP055855644, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.9b01810 *
MERCER STEPHEN E.; CHATURVEDULA PRASAD V.; CONWAY CHARLES M.; COOK DEBORAH A.; DAVIS CARL D.; PIN SOKHOM S.; MACCI ROBERT; SCHARTM: "Azepino-indazoles as calcitonin gene-related peptide (CGRP) receptor antagonists", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 31, 21 October 2020 (2020-10-21), Amsterdam NL , pages 1 - 4, XP086408197, ISSN: 0960-894X, DOI: 10.1016/j.bmcl.2020.127624 *

Also Published As

Publication number Publication date
AR126955A1 (en) 2023-12-06
WO2023034467A2 (en) 2023-03-09

Similar Documents

Publication Publication Date Title
PH12020551572A1 (en) Heterocyclic compounds as immunomodulators
JOP20220179A1 (en) N4-hydroxycytidine and derivatives and anti-viral uses related thereto
MX2022012780A (en) Fused tricyclic kras inhibitors.
PH12019500845A1 (en) Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof
AU2018243463A8 (en) 11,13-modified saxitoxins for the treatment of pain
MX2023001997A (en) Bicyclic compounds, compositions and use thereof.
PH12019501371A1 (en) PYRIMIDINE TRICYCLIC ENONE DERIVATIVES FOR INHIBITION OF RORy AND OTHERS USES
PH12018501567A1 (en) New substituted cyanoindoline derivatives as nik inhibitors
MX2022007155A (en) Novel chroman derivatives having estrogen receptor degradation activity and uses thereof.
MX2021006619A (en) Tyrosine kinase inhibitors, compositions and methods there of.
MX2022006086A (en) Pyridopyrimidinone derivatives as ahr antagonists.
PH12019502086A1 (en) Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
ZA202201364B (en) Deuterated compounds for use in the treatment of cancer
CA2902116C (en) Pyrrolopyridine derivatives and their use as inhibitors of ssao activity
MX2022009043A (en) Sulfonimidamide compounds as nlrp3 modulators.
MX2022001952A (en) Alkynyl quinazoline compounds.
MX2022002646A (en) Ruxolitinib formulation for reduction of itch in atopic dermatitis.
AU2022367432A1 (en) Quinoline compounds as inhibitors of kras
CR20210544A (en) ][1,2,4]thiadiazine 1,1-dioxide derivatives as inhibitors of mrgx2
WO2023034467A3 (en) Cgrp antagonists for treating skin conditions
MX2022013396A (en) Tetrahydroisoquinoline compounds as nrf2 activators.
WO2021161023A8 (en) Compounds useful in inhibiting ketohexokinase and methods of making and using the same
AU2021242808A8 (en) Solid dispersions of amorphous 3, 4-diphenyl-4, 5-dihydro- 1H-pyrazole derivatives, compositions comprising them and uses thereof as cannabinoid CB1 receptor inhibitors
MX2022015739A (en) Allosteric egfr inhibitors and methods of use thereof.
MX2022013398A (en) Tetrahydroisoquinoline compounds as nrf2 activators.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22865540

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE